Drug intelligence / Profile preview

BAT-100

Development stage: Preclinical
Lead developer: Bright Angel Therapeutics
Modality: Small Molecules

Overview

BAT-100 is a preclinical-stage small molecule inhibitor being developed by Bright Angel Therapeutics for the treatment of drug-resistant and invasive fungal infections. The compound is designed to target critical fungal stress response pathways that are essential for the maintenance and emergence of antifungal drug resistance. By inhibiting these fungal-selective targets, BAT-100 aims to provide broad-spectrum activity against both drug-sensitive fungal isolates and those with established resistance to conventional antifungal therapies. The drug was developed utilizing Schrödinger's computational drug discovery platform in conjunction with proprietary biological technologies.

Targets

HSP90 (Heat shock protein 90 chaperone complex)

Beyond the preview

Go deeper on BAT-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAT-100.

Explore the full profile